News And Media

  • 2017

     

    STENTYS is strengthening its Board by co-opting two new independent members

    03/04/2017

    STENTYS is strengthening its Board  by co-opting two new independent members

    Prof. Christian Spaulding, Head of the Interventional Cardiology department  at the Georges-Pompidou European Hospital in Paris 

    Sophie Baratte, CEO of medical technology company Cellnovo

    PARIS - April 3, 2017 – 6 pm CET - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the XPOSITION S self-apposing coronary stent, today announces that the STENTYS Board of Directors has decided to co-opt Professor Christian Spaulding and Mrs. Sophie Baratte as independent Board members. 
     

    Download File
     

    2016 Annual Results

    21/03/2017

    STENTYS Reports its 2016 Annual Results 
     
    ▪ Revenues up 20% to €7.3 million

    ▪ 12% reduction in the operating loss 

    ▪ Restructuring plan completed

    ▪ Cash position of €17.0 million at end-2016

    PARIS - March 21, 2017 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its annual results for the year to December 31, 2016, as approved by the Board of Directors on March 21, 2017. The Company has decided to bring their publication forward by a day in anticipation of its participation in the Portzamparc Forum on March 22, 2017.
     

    Download File
     

    STENTYS Completes Enrollment of the TRUNC Study

    27/07/2017

    STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy  of Xposition S in Left Main Artery Lesions 
     
    200 patients enrolled in the TRUNC clinical trial


    PARIS – July 27, 2017 – 6.15 pm CEST – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the Xposition S Sirolimus-eluting self-apposing coronary stent, today announces that the enrollment of the 200 patients for the TRUNC trial has been completed as scheduled

    Download File
     

    STENTYS announces the pre-commercialization of SERPENTIS, its new latest-generation of active stent

    08/11/2017

    STENTYS announces the pre-commercialization of SERPENTIS, its new latest-generation of active stent 

    PARIS – November 8, 2017 – 6.00 pm (CET) – STENTYS (FR0010949404 – STNT), a medical technology company commercializing the Xposition S self-apposing coronary stent, today announces the pre-commercialization of Serpentis, its new Sirolimus-eluting stent with a bio-absorbable coating for routine procedures.

    Download File
     

    Revenues for the Third Quarter of 2017: Continued Growth for the Xposition S Stent

    12/10/2017

    Revenues for the Third Quarter of 2017:  Continued Growth for the Xposition S Stent  
     
    ▪ Quarterly sales of the Xposition S stent up +19% in volume

    ▪ Third quarter revenues: €1.6 million (-4.7%)

    PARIS - October 12, 2017 - 5.45 pm (CEST) – STENTYS (FR0010949404 – STNT), a medical technology company commercializing the Xposition S self-apposing coronary stent, today reports its revenues for the third quarter and first nine months of 2017.
     

    Download File
     

    2017 half-year results

    02/10/2017

    2017 half-year results

    Xposition S stent sales up by +20% in volume 

    30% reduction in operating loss  

    Cash position of €10.3 million at June 30, 2017

    PARIS - October 2, 2017 – 7.30 am (CEST) STENTYS (FR0010949404 — STNT), a medical technology company commercializing the first and only Self-Apposing® coronary stent, today announces its half-year results to June 30, 2017, as approved by the Board on September 29, 2017.  The 2017 half-year financial report is available on the Company’s website, www.stentys.com, under Investors / Filings / Accounts & financial reports (http://www.stentys.com/28/6/documents/documentation.html).
     
     

    Download File
     

    STENTYS is strengthening its Board by co-opting two new independent members

    03/04/2017

    STENTYS is strengthening its Board  by co-opting two new independent members

    Prof. Christian Spaulding, Head of the Interventional Cardiology department  at the Georges-Pompidou European Hospital in Paris 

    Sophie Baratte, CEO of medical technology company Cellnovo 

    PARIS - April 3, 2017 – 6 pm CET - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the XPOSITION S self-apposing coronary stent, today announces that the STENTYS Board of Directors has decided to co-opt Professor Christian Spaulding and Mrs. Sophie Baratte as independent Board members. 
     

    Download File
     
  • 2016

     

    STENTYS Reports 26% Year-over-Year Growth in Nine-Month 2016 Revenues

    12/10/2016

    Download File
     

    STENTYS: Appointment of Cardiovascular Device Veteran as New CEO

    06/07/2016

    STENTYS: Appointment of Cardiovascular Device Veteran  as New CEO      

    • Christophe Lottin, ex second in command at stent company Hexacath, brings 20 years of sales and management experience 
    • Gonzague Issenmann recruited his successor to ensure the company he has created continues to thrive     

    PRINCETON, N.J. and PARIS – July 4, 2016 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that the Board of Directors has appointed Christophe Lottin as the new Chief Executive Officer of the Company. Gonzague Issenmann has organized his succession and will ensure a smooth transition over the next quarter.  

    Download File
     

    STENTYS Announces CE Marking of its longest Xposition stent

    08/06/2016

    STENTYS Announces CE Marking  of its longest Xposition stent   

    Portfolio expansion with the addition of a 37 mm stent  designed for long coronary lesions   

    PRINCETON, N.J. and PARIS – June 8, 2016 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that it has received CE Marking for the longest version of its Xposition S Sirolimuseluting self-apposing stent.   

    Download File
     

    STENTYS Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Artery Disease

    21/03/2016

    STENTYS Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Artery Disease     

    PRINCETON, N.J. and PARIS – March 21, 2016 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that Xposition S, the Sirolimus-eluting Self-Apposing stent, received CE Marking for the treatment of Unprotected Left Main Coronary artery disease on the basis of the results from a study published last year in the peer-reviewed journal Catheterization and Cardiovascular Interventions (CCI).

    Download File
     

    Launch of the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication

    08/02/2016

    STENTYS initiates the Commercialization  of the first Self-Expanding Drug-Eluting stent  for the Below-The-Knee Indication     

    PRINCETON, N.J. and PARIS – February 8, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces the first distribution agreements for its drug-eluting stent for treating BTK (Below-The Knee) arteries in Germany and Belgium, making it the first self-expanding drugeluting stent commercialized for this indication in Europe. 

    Download File
     

    STENTYS: First Intervention with the Self-Apposing Drug-Eluting Stent for Lower Limbs broadcasted live at LINC international congress

    28/01/2016

    STENTYS: First Intervention with the Self-Apposing  Drug-Eluting Stent for Lower Limbs  broadcasted live at LINC international congress   

    Two procedures successfully performed at Leipzig University hospital   

    PRINCETON, N.J. and PARIS - January 28, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that the first interventions using its self-expanding drug-eluting stent to treat BTK (below-the-knee) arterial disease have been performed during two live-case sessions broadcasted during LINC, the Leipzig Interventional Course, the largest congress on peripheral pathologies. 

    Download File
     

    Results of Self-Apposing Sirolimus-Eluting Stent Trial Published in EuroIntervention

    29/02/2016

    STENTYS: Results of Self-Apposing Sirolimus-Eluting Stent Trial Published in EuroIntervention   

    APPOSITION IV trial demonstrated superior apposition and faster healing  than with conventional stents   

    PRINCETON, N.J. and PARIS - February 29, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that the results of the APPOSITION IV trial, which compared the STENTYS SelfApposing Sirolimus-eluting coronary stent to the Medtronic Resolute® stent in patients presenting with ST-segment elevation myocardial infarction (STEMI), were published in the February issue of EuroIntervention , the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

    Download File
     

    Succes of a 12.6m rights issue

    04/03/2016

    STENTYS successfully completes €12.6 million capital increase 

    PRINCETON, N.J. and PARIS – March 4, 2016 – STENTYS (the « Company » — STNT – FR0010949404), announces the successful completion of its capital increase with preemptive rights opened for subscription from February 15, 2016 to February 26, 2016.

    Download File
     

    41% Increase in Revenues in the Second Quarter of 2016

    12/07/2016

    STENTYS: 41% Increase in Revenues  in the Second Quarter of 2016 

    PRINCETON, N.J. and PARIS - July 12, 2016 - STENTYS (FR0010949404  STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenues and cash position at June 30, 2016.

    Download File
     

    Convening of another Annual General Meeting on June 16, 2016

    12/05/2016

    STENTYS: convening of another Annual  General Meeting on June 16, 2016

    PRINCETON, N.J. and PARIS - May 12, 2016 - STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, informs its shareholders that the Annual General Meeting held on May 11, 2016 was unable to deliberate, as the required quorum was not reached

    Download File
     

    STENTYS Reports 26% Year-over-Year Growth in Nine-Month 2016 Revenues

    12/10/2016

    STENTYS Reports 26% Year-over-Year Growth  in Nine-Month 2016 Revenues

     The number of stents implanted worldwide has exceeded 20,000
     
     Left main coronary artery clinical trial on track
     
     Sound cash position of €15.7m at September 30, 2016 

    PRINCETON, N.J. and PARIS - October 12, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenue for the third quarter and first 9 months to September 30, 2016.

    Download File
     

    STENTYS Reports 38% Increase in Revenues in First Quarter 2016

    13/04/2016

    STENTYS Reports 38% Increase in Revenues  in First Quarter 2016

    PRINCETON, N.J. and PARIS – April 13, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenues for the first quarter of 2016.

    Download File
     

    STENTYS Reports 81% Year-over-Year Growth in Fourth-Quarter 2015 Revenues

    13/01/2016

    STENTYS Reports 81% Year-over-Year Growth in Fourth-Quarter 2015 Revenues

    Annual Revenues of €6.1 million, up 59% over prior year

    PRINCETON, N.J. and PARIS - January 13, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenues for the fourth quarter and full year 2015.
     

    Download File
     

    2016 First-Half Results

    15/09/2016

    STENTYS Reports 2016 First-Half Results

    Revenues up 40% 

    Gross margin up to 59%  

    26% decrease in the operating loss 

    Solid cash position of €18.1 million 

    PRINCETON, N.J. and PARIS - September 15, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its half-year results to June 30, 2016, as approved by the Board meeting of September 15, 2016. 
     

    Download File
     

    2015 Annual Results

    16/03/2016

    STENTYS Reports 2015 Annual Results

    Annual revenues up 58% 

    Gross margin up 1,671 bp  

    48% reduction in the operating loss 

    Cash position strengthened through the €12.6 million rights issue  of March 8, 2016 

    PRINCETON, N.J. and PARIS - March 16, 2016 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its annual results for the year to December 31, 2015, as approved by the Board of Directors on March 15, 2016. 
     

    Download File
     
  • 2015

     

    STENTYS’ Next-Generation of Self-Apposing Stent System Receives CE Marking Ahead of Plan

    28/04/2015

    STENTYS’ Next-Generation of Self-Apposing Stent System  Receives CE Marking Ahead of Plan   

    Xposition S™ combines STENTYS Sirolimus-eluting Stent with New and Unique Delivery Catheter that Replicates Conventional Stent Implantation Technique   

    Product to be Introduced at EuroPCR on May 19th     

    PRINCETON, N.J. and PARIS – April 28, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced it received CE Marking for its new Self-Apposing stent system ahead of plan, which will allow the Company to market the new products in Europe and in all the other countries where this certification is recognized. STENTYS will officially launch Xposition S™ at the EuroPCR conference on May 19, 2015.

    Download File
     

    Results of largest STENTYS Stent Trial in Myocardial Infarction Published in EuroIntervention

    23/02/2015

    Results of largest STENTYS Stent Trial in Myocardial Infarction Published in EuroIntervention   APPOSITION III showed excellent safety profile of the Self-Apposing technology     

    PRINCETON, N.J. and PARIS – February 23, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that the one-year clinical outcomes of the APPOSITION III registry (see the press release from March 9, 2013), which studied the STENTYS Self-Apposing coronary stent in patients presenting with ST-segment elevation myocardial infarction (STEMI), have been published in EuroIntervention , the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

    Download File
     

    New Self-Apposing Stent Study in Left Main Coronary Artery

    12/02/2015

    STENTYS Announces the Publication of New Self-Apposing Stent Study in Left Main Coronary Artery    

    Study published online in the Catheterization and Cardiovascular Interventions Journal showed superiority of Self-Apposing technology in Opening the Heart’s Main Artery   

    PRINCETON, N.J. and PARIS – February 12, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that new data on the Self-Apposing stent in the challenging treatment of the Left Main coronary artery was published in the peer-reviewed journal C a t h e t e r i z a t i o n a n d Cardiovascular Interventions (CCI) and the authors concluded that the STENTYS DES offers a valid treatment alternative for this indication.  

    Download File
     

    STENTYS Expands Benefits of First Drug-Eluting, Self-Expanding Stent to Lower Limb Artery Disease

    28/01/2015

    STENTYS Expands Benefits of First Drug-Eluting,  Self-Expanding Stent to Lower Limb Artery Disease Clinical Trial Found STENTYS Treatment Prevented   Amputation in 99% of Cases   

    PRINCETON, N.J. and PARIS – January 28, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that its unique Drug-Eluting and Self-Expanding stent was evaluated in 70 patients suffering from critical limb ischemia (CLI) and prevented foot amputation in 99% of them. 

    Download File
     

    STENTYS: convening of another combined Shareholders’ Meeting on June 15, 2015

    05/05/2015

    STENTYS: convening of another combined  Shareholders’ Meeting on June 15, 2015 

    PRINCETON, N.J. and PARIS - May 5, 2015 - STENTYS (FR0010949404 - STNT - PEA PME eligible), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, informs its shareholders that today’s combined Shareholders’ Meeting was unable to deliberate, as the required quorum was not reached. Shareholders are therefore invited to attend another combined Shareholders’ Meeting, on the second call, to be held on Monday June 15, 2015 from 4 pm at “Club Confair”, 54 rue Laffitte 75009, Paris, the agenda of which will be the same.
     

    Download File
     

    STENTYS Reports 40% Increase in Revenues in Second Quarter of 2015

    08/07/2015

    STENTYS Reports 40% Increase  in Revenues in Second Quarter of 2015  

    PRINCETON, N.J. and PARIS - July 8, 2015 - STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenues and cash position at June 30, 2015.

    Download File
     

    STENTYS Reports First Quarter 2015 Revenues Rose 28

    16/04/2015

    STENTYS Reports First Quarter 2015 Revenues Rose 28%  

    PRINCETON, N.J. and PARIS - April 16, 2015 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces revenues for the first quarter of 2015.

    Download File
     

    Report on the Combined Shareholders’ Meeting of June 15, 2015

    16/06/2015

    Report on the Combined Shareholders’ Meeting of June 15, 2015

    PRINCETON, N.J. & PARIS - June 16, 2015 - STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, informs its shareholders that today’s combined Shareholders’ Meeting was able to take place, given the reach of its quorum.

    Download File
     

    First Half 2015 Financial Results

    17/09/2015

    STENTYS Reports First Half 2015  Financial Results

    Revenues up 35% 

    Gross margin up 1,400 basis points to 53%  

    59% reduction in the net loss  

    Solid cash position of €12.7 million  


    PRINCETON, N.J. and PARIS - September 17, 2015 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its half-year results for the six months ended June 30, 2015, as approved by the Board meeting of September 17, 2015. 
     

    Download File
     

    2016 Financial Agenda

    22/12/2015

    2016 Financial Calendar

    PRINCETON, N.J. and PARIS – December 22, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, announced today its preliminary financial calendar for 2016.

    Download File
     

    STENTYS 2014 Annual Revenues up 13% to €3.9 Million

    22/01/2015

    STENTYS 2014 Annual Revenues up 13% to €3.9 Million 

    • Cash position of €18.6 million at December 31, 2014

    • Three product launches expected in 2015

    PRINCETON, N.J. and PARIS - January 22, 2015 – STENTYS (FR0010949404 — STNT – PEA PME eligible), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its consolidated revenues for the 4th quarter and full year 2014.

    Download File
     

    2014 Annual Results

    31/03/2015

    STENTYS 2014 Annual Results

    Annual revenues up 13% 

    Solid cash position of €18.6 million allowing the commercial launch of the new product portfolio 

    Accrual for the APPOSITION V clinical trial reduced by almost €1.8 million compared to June 30, 2015 


    PRINCETON, N.J. and PARIS - March 31, 2015 - STENTYS (FR0010949404 — STNT – PEA PME eligible), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today reported its financial results for the year to December 31, 2014, approved by the Board of Directors on March 26, 2015. Audit procedures relative to the consolidated accounts have been carried out and the auditor’s report is currently under finalization.
     
     

    Download File
     

    STENTYS: Enrollment Completion of MiStent Randomized Trial against Xience

    09/12/2015

    STENTYS: Enrollment Completion of MiStent Randomized Trial against Xience
     
    DESSOLVE III clinical trial enrolled 1,400 “all-comers” patients 

    Primary endpoint results to be announced in H1 2017


    PRINCETON, N.J. and PARIS - December 9, 2015 - STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, announced today the completion of patient enrollment in DESSOLVE III, a 1,400 patient randomized clinical trial comparing MiStent SES® Sirolimus Eluting Absorbable Polymer Coronary Stent System to Abbott’s Xience® stent.

    Download File
     

    First Clinical Experience with Xposition shows 100% implantation success, Confirms Ease of Use

    19/05/2015

    STENTYS: First Clinical Experience with Xposition shows 100% implantation success, Confirms Ease of Use  

    Results of SETUP Trial presented at EuroPCR and Published on-line  in EuroIntervention 

    PRINCETON, N.J. and PARIS – May 19, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that the findings of the first Xposition® clinical experience, as part of the SETUP trial, were presented at the EuroPCR conference. The results of this study were also published today in the online edition of EuroIntervention.

    Download File
     

    STENTYS Announces the Publication of New Self-Apposing Stent Study in Left Main Coronary Artery

    12/02/2015

    STENTYS Announces the Publication of New Self-Apposing Stent Study in Left Main Coronary Artery 

    Study published online in the Catheterization and Cardiovascular Interventions Journal showed superiority of Self-Apposing technology in Opening the Heart’s Main Artery 

    PRINCETON, N.J. and PARIS – February 12, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced that new data on the Self-Apposing stent in the challenging treatment of the Left Main coronary artery was published in the peer-reviewed journal C a t h e t e r i z a t i o n a n d Cardiovascular Interventions (CCI) and the authors concluded that the STENTYS DES offers a valid treatment alternative for this indication.
     

    Download File
     

    STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years

    12/10/2015

    STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years 

    Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco

    PRINCETON, N.J. and PARIS – October 12, 2015 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that three-year follow-up imaging data from the STENTYS arm of the APPOSITION IV clinical study confirms the long-term performance of the sirolimus-eluting Self-Apposing stent. The data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, CA.
     

    Download File
     
  • 2014

     

    STENTYS enrichit son offre de produits à toutes les indications coronaires par un accord exclusif avec Micell pour distribuer son stent actif innovant

    03/11/2014

    STENTYS Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell To Distribute Its Novel Drug-Eluting Stent
     

    PRINCETON, N.J. and PARIS – November 3, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announced it has entered into a five year agreement with Micell Technologies Inc. to be the exclusive distributor of the MiStent coronary stent worldwide (excluding the United States, Canada, China, South Korea and Japan).

    Download File
     

    STENTYS Reaches 10,000 Self-Apposing Stent implantations

    03/09/2014

    STENTYS Reaches 10,000  Self-Apposing Stent implantations

    PRINCETON, N.J. and PARIS – September 3rd, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the Self-Apposing stent has been implanted over 10,000 times in patients worldwide. This milestone further illustrates the popularity of STENTYS’ technology among cardiologists in Europe and a growing number of regions globally.
     

    Download File
     

    STENTYS to Acquire Stent Delivery Technology for Its Next-Generation of Self-Apposing Stents

    04/06/2014

    STENTYS to Acquire Stent Delivery Technology for Its Next-Generation of Self-Apposing Stents 


    Unique Delivery Catheter Replicates 

    Conventional Stent Implantation Technique

    PRINCETON, N.J. and PARIS – June 4, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.

    Download File
     

    STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis

    07/05/2014

    STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis 

    Study conducted by Dr Virmani further supports the Self-Apposing technology’s scientific rationale 

    PRINCETON, N.J. and PARIS – May 6, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® Stent for treating acute myocardial infarction (AMI), today announced the publication of an article in the Journal of the American College of Cardiology (JACC) entitled, "Causes of Early Stent Thrombosis in Patients Presenting with Acute Coronary Syndrome: An Ex Vivo Human Autopsy Study."
     

    Download File
     

    STENTYS Reallocates Resources to focus on its Advanced Drug-Eluting Stent Program

    31/07/2014

    STENTYS Reallocates Resources to focus on its Advanced 

    Drug-Eluting Stent Program

    PRINCETON, N.J. and PARIS – July 31, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces that it has discontinued enrollment of the APPOSITION V trial evaluating its bare metal stent (BMS) and that the Company will instead direct those financial resources towards developing its next-generation Sirolimus-eluting stents (SES) on a new delivery catheter. 

    Download File
     

    STENTYS’ Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology

    29/04/2014

    STENTYS’ Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology

    STENTYS highlighted as a solution to minimize stent malapposition in clinical practice

    PRINCETON, N.J. and PARIS – April 29, 2014 — STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent for treating acute myocardial infarction (AMI), today announced that the Journal of the American College of Cardiology (JACC) published a “State-of-the-Art Paper” entitled “Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition,” which highlights STENTYS’ Self-Apposing Stent among novel devices to minimize stent malapposition, also known as incomplete stent apposition (ISA), in clinical practice.

     

    Download File
     

    STENTYS’ Sirolimus-Eluting Stent Receives CE Marking

    27/10/2014

    STENTYS’ Sirolimus-Eluting Stent Receives CE Marking

    PRINCETON, N.J. and PARIS – October 27, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces it received CE Marking for its Sirolimus-Eluting Stent (SES). The CE Marking will allow the Company to market its SES in Europe immediately and, starting in 2015, in the many other countries where the Company has commercial activity. 
     

    Download File
     

    STENTYS Self-Apposing Stent Featured Prominently at 2014 EuroPCR Conference

    27/05/2014

    STENTYS Self-Apposing Stent Featured Prominently  at 2014 EuroPCR Conference

    Over 20 case presentations  

    3 clinical trials in “Hotline”

    Late Breaking sessions 

    2 dedicated symposia


    PRINCETON, N.J. and PARIS – May 27, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today reported on multiple sessions, symposia and case presentations featuring STENTYS stents during the annual EuroPCR meeting held in Paris last week.
     

    Download File
     

    STENTYS Adds Branch Office in Dubai

    25/09/2014

    STENTYS Adds Branch Office in Dubai

    PRINCETON, N.J. and PARIS – September 25, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces the creation of a branch office in Dubai (United Arab Emirates).

    Download File
     

    STENTYS Wins Large Regional Tender in Middle East

    20/10/2014

    STENTYS Wins Large Regional Tender in Middle East 


    PRINCETON, N.J. and PARIS – October 20, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced that the 2014 SGH tender has awarded more than 1,000 coronary stents to STENTYS.

    Download File
     

    STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients

    20/05/2014

    STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients

    Final Results from APPOSITION IV Study Presented at EuroPCR: 

    - No late loss and perfect strut coverage at 9-months 

    - Faster arterial healing compared to conventional drug-eluting stents

     
    PRINCETON, N.J. and PARIS – May 20, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today presented final results from the APPOSITION IV study of its new Self-Apposing sirolimus-eluting stent (SES) during the Hotline session at the EuroPCR conference in Paris.

    Download File
     

    STENTYS Stent continues to show low mortality two years after treatment of a heart attack

    16/09/2014

    STENTYS Stent continues to show low mortality two years after treatment of a heart Attack

    Final 2 Year Results from APPOSITION III Study Pres ented Today at TCT Conference in Washington, D.C 


    PRINCETON, N.J. and PARIS – September 16, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced the results of the 1,000 patient APPOSITION III clinical study at two years after the treatment of a severe heart attack. 
     

    Download File
     

    STENTYS appoints Medical Device Executive to its Board of Directors

    10/04/2014

    STENTYS appoints Medical Device Executive to its Board of Directors

    Dianne Blanco, CEO of Orteq, brings 20 years of medical technology management experience

    PRINCETON, N.J. and Paris - April 10, 2014 - STENTYS (FR00A0949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing®  stent to treat acute myocardial infarction (AMI), today announced that Dianne Blanco has been appointed as a Director to replace the representative from Omnes Capital venture capital fund. 

    Download File
     

    STENTYS Expands Marketing of the Self-Apposing Stent in South America

    09/07/2014

    STENTYS Expands Marketing of the Self-Apposing Stent  in South America 


    PRINCETON, N.J. and PARIS – July 9, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced its first distribution contracts in South America.
     

    Download File
     

    STENTYS Expands Marketing of its Stents in Asia

    08/01/2014

    STENTYS Expands Marketing of its Stents in Asia 
    Distribution agreements signed in Singapore, Hong Kong and Malaysia

    PRINCETON, N.J. and PARIS - January 8, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent for treating acute myocardial infarction (AMI), today announced the signing of the first distribution partnerships for its stents in Asia.
     

    Download File
     

    Financial agenda 2014

    06/01/2014

    Agenda of financial events 2014

    PRINCETON, N.J. and PARIS – January 6, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today its preliminary financial agenda for 2014.

    Download File
     

    STENTYS Completes the Acquisition of Cappella Peel Away Inc.

    12/06/2014

    STENTYS Completes the Acquisition  of Cappella Peel Away Inc.  

    PRINCETON, N.J. and PARIS – June 12, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today presented the final terms of the acquisition of Cappella Peel Away Inc. (Delaware, USA) and of its assets relating to a novel stent delivery system for a total amount of €1 million in stock and cash. 

    Download File
     

    2013 full-year results

    13/03/2014

    STENTYS Reports 2013 Financial Results  

        Annual revenues up 34%  

     Improvement in the bottom line for historical activity  

     Solid cash position of €31.9 million 

     STENTYS added to the new Euronext CAC PME index 

     Marie Meynadier to represent BPI-France on Board of Director

    PRINCETON, N.J. and PARIS - March 13, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat acute myocardial Infarction (AMI), today announced its annual results for the financial year to December 31, 2013, approved by the Board of Directors at its meeting on March 6, 2014.
     

    Download File
     

    STENTYS Secures a Standby Equity Facility

    14/05/2014

    STENTYS Secures a Standby Equity Facility  

    PRINCETON, N.J. and PARIS - May 14, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced that it has entered into a Standby Equity Facility with Société Générale, exercisable by tranches at STENTYS’ discretion, as authorized by the Shareholders’ Meeting of May 15, 2013.

    Download File
     

    First Half 2014 Financial Results

    22/09/2014

    STENTYS Reports First Half 2014 Financial Results  

    Revenues up 18% 

    Solid cash position of €23.1 million 

    One-time accrual for the potential future costs of the APPOSITION V trial

    PRINCETON, N.J. and PARIS - September 22, 2014 - STENTYS (FR0010949404 — STNT – PEA-PME eligible), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces its half-year results for the six months ended June 30, 2014, as approved by the Board meeting of September 19.
     

    Download File
     

    2013 Annual Revenues Up 34% From 2012

    23/01/2014

    STENTYS 2013 Annual Revenues Up 34% From 2012 

    • Fourth quarter growth up 39% 

    • Cash position of €31 million at December 31, 2013 

    • 2014: numerous clinical and commercial expected milestones  

    PRINCETON, N.J. and PARIS - January 23, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced its consolidated, audited revenues for the fourth quarter and full year 2013.
     

    Download File
     

    STENTYS Revenues for the First 9 Months of 2014 up 16.9 percent

    23/10/2014

    STENTYS Revenues for the First 9 Months  of 2014 up 16.9% 

    PRINCETON, N.J. and PARIS - October 23, 2014 - STENTYS (FR0010949404 — STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces revenues for the third-quarter and ninemonths ended September 30, 2014.
     

    Download File
     

    STENTYS First Quarter Revenues Up 18% from 2013

    24/04/2014

    STENTYS: First Quarter Revenues Up 18% from 2013 

    PRINCETON, N.J. and PARIS - April 24, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat Acute Myocardial Infarction (AMI), today announces its revenues for the first quarter ending March 31, 2014.

    Download File
     

    STENTYS First Half 2014 Revenues Rise 18pc

    24/07/2014

    STENTYS First Half 2014 Revenues Rise 18% 

    PRINCETON, N.J. and PARIS – July 24, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces revenues for the second quarter and first half of 2014, as well as cash position at June 30, 2014.

    Download File
     

    STENTYS to Report First-Half Results on September 22, 2014

    25/08/2014

    STENTYS to Report First-Half Results  on September 22, 2014

    PRINCETON, N.J. and PARIS – August 25, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces it will report financial results for the first half of 2014 on September 22, 2014, before the market opening, which is a change from the originally announced date of August 28. The Company already reported its first half 2014 revenues and cash position on July 24. 
     

    Download File
     

    Communiqué de mise à disposition du Document de référence 2013

    30/10/2014

    Mise à disposition du document de référence 2013

    PRINCETON, N.J. et PARIS - le 30 octobre 2014 - STENTYS (FR0010949404 — STNT – éligible PEA PME), société de technologie médicale qui commercialise le premier et le seul stent auto-apposant coronaire, annonce que son Document de référence 2013 a été déposé auprès de l’Autorité des Marchés Financiers (AMF) le 29 octobre 2014 sous le numéro D.14-1026.

    Download File
     

    STENTYS Reallocates Resources to focus on its Advanced Drug-Eluting Stent Program

    31/07/2014

    STENTYS Reallocates Resources to focus on its Advanced  Drug-Eluting Stent Program  

    PRINCETON, N.J. and PARIS – July 31, 2014 – STENTYS (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces that it has discontinued enrollment of the APPOSITION V trial evaluating its bare metal stent (BMS) and that the Company will instead direct those financial resources towards developing its next-generation Sirolimus-eluting stents (SES) on a new delivery catheter. 
     

    Download File
     

    STENTYS shares eligible for new PEA-PME savings plan

    31/03/2014

    STENTYS shares eligible for new  PEA - PME savings plan

    PRINCETON, N.J. and PARIS - March 31, 2014 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today confirmed that its shares are eligible for the new “ PEA PME ” SME equity savings plan.
     
     

    Download File
     
  • 2013

     

    STENTYS Self-Apposing Stent performs well in new coronary indications

    30/10/2013

    STENTYS Self-Apposing Stent performs well in new coronary indications

    Two stud ies assessing STENTYS in indications  outside of heart attacks presented at TCT 2013 


    PRINCETON, N.J. and PARIS – October 30, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced new data this week in indications outside of myocardial infarction. Results from the OPEN II study and a series from the Amsterdam Medical Center were presented during the TCT (Transcatheter Cardiovascular Therapeutics) conference in San Francisco.

    Download File
     

    STENTYS Sirolimus-eluting stent demonstrates faster arterial healing than conventional drug-eluting stent

    29/10/2013

    STENTYS Sirolimus-eluting stent  demonstrates faster arterial healing  than conventional drug-eluting stentS

    4 - month results of APPOSITION I V Study presented at TCT 2013 


    PRINCETON, N.J. and PARIS – October 29, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today results from the 4-month arm of the APPOSITION IV study of its new Self-Apposing Sirolimus-eluting stent during the TCT (Transcatheter Cardiovascular Therapeutics) conference. 
     

    Download File
     

    STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.13

    26/02/2013

    STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.13

    Educational Symposium Also to Highlight FDA - A pproved U.S. P ivotal S tudy  for Self - Apposing ® S tent in STEMI Patients 

    PRINCETON, N.J. and PARIS – February 26, 2013 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that results for the primary endpoint in the APPOSITION III study (MACE at one year on 1,000 STEMI patients) will be presented during ACC.13, the American College of Cardiology’s Scientific Session & Expo, March 9-11, 2013 in San Francisco. Prof. Gilles Montalescot, M.D., Ph.D, Head of the Cardiac Care Unit at Pitié-Salpêtrière Hospital (Paris), will present “One Year Clinical Results on 1,000 STEMI Patients Treated With a Self-Expanding Coronary Stent (APPOSITION III)” during Session #2667 of the Featured Clinical Research I: Interventional session on Saturday, March 9, 2013 at 3:00 p.m. 

    Download File
     

    Further Data on STENTYS Self-Apposing Stent Reinforces Strength of Clinical Results

    22/05/2013

    Further Data on STENTYS Self-Apposing Stent Reinforces Strength of Clinical Results

    New Sub - group Analysis of APPOSITION III Presented at EuroPCR  in Paris

     
    PRINCETON, N.J. and PARIS – May 22, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today new one-year data from the APPOSITION III clinical trial at the international EuroPCR conference in Paris. APPOSITION III was designed to assess the long-term performance of STENTYS Self-Apposing Stents in routine clinical practice in Europe among 1,000 patients suffering a heart attack (ST-elevation myocardial infarction or STEMI).
     

    Download File
     

    STENTYS to Present first results of Sirolimuseluting Self-Apposing® Stent at TCT Conference

    21/10/2013

    STENTYS to Present first results of Sirolimuseluting Self-Apposing® Stent at TCT Conference

    PRINCETON, N.J. and PARIS – October 21, 2013 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the 4-month results of the APPOSITION IV trial will be disclosed during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Dr Robert-Jan van Geuns, M.D., Ph.D., of Erasmus MC (Rotterdam, the Netherlands) and co-Principal Investigator, will present “Sirolimus-Eluting Self-Apposing Stent: Preliminary Results of the APPOSITION IV Study and Future Developments”, during a Satellite Symposium on October 29 at 7:00am

    Download File
     

    STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial

    20/05/2013

    STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial 

    PRINCETON, N.J. and PARIS – May 20, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that the first patient was enrolled in APPOSITION V, the pivotal FDA-approved IDE trial which will enable the Company to apply for marketing approval of the Self-Apposing Stent in the United States.
     

    Download File
     

    STENTYS Self-Apposing Stent Approved in Europe for Additional Coronary Indications

    10/07/2013

    STENTYS Self-Apposing Stent Approved in Europe for Additional Coronary Indication

    New market segments represent 10% of all coronary interventions

     
    PRINCETON, N.J. and PARIS – July 10, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that it received approval from its European Notified Body to expand the CE Mark indications of the Self-Apposing stent.
     

    Download File
     

    STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials

    09/03/2013

    STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials

    One - year APPOSITION III results in 1,000 heart attack patients presented at ACC.13

     
    PRINCETON, N.J. and PARIS – March 9, 2013 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today one-year results of the APPOSITION III clinical trial in 1,000 patients post treatment of a severe heart attack at ACC.13, the American College of Cardiology’s Scientific Session & Expo. 
     

    Download File
     

    STENTYS clinical study demonstrating superiority of SelfApposing® stents over conventional stents published in American College of Cardiology journal

    03/01/2013

    STENTYS clinical study demonstrating superiority of SelfApposing® stents over conventional stents published in American College of Cardiology journal

    APPOSITION II randomized study showed 28% malapposition in conventional stents versus 0% in STENTYS stents

    PRINCETON, N.J. and PARIS – January 3, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today that results from the foundational APPOSITION II clinical trial were published in the December issue of the American College of Cardiology’s journal, JACC Cardiovascular Interventions . The manuscript, also available online is titled, “Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results from the APPOSITION II Study”. 

    Download File
     

    PRESS RELEASE

    02/05/2013

    PRESS RELEASE

    PRINCETON, N.J. and PARIS - 2 May 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced notification that the shares and securities now owned by Mr. Jacques Séguin are all bound by lock-up agreement.

    Download File
     

    Financial agenda for 2013

    10/01/2013

    Agenda of financial events 2013 


    PRINCETON, N.J. and PARIS – January 10, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today its preliminary financial agenda for 2013.
     

    Download File
     

    2012 annual revenues up 77% over prior year

    23/01/2013

    STENTYS 2012 annual revenues up 77%  over prior year 

    • Strong continued revenue growth 

    • 2013 : acceleration in scientific and marketing developments 

    • Cash position of €45.6 million at 31 December 2012

    • STENTYS now listed on compartment B of NYSE Euronext 

    PRINCETON, N.J. and PARIS - 24 January 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today reports its fourth quarter and full year revenuesi for the year 2012.

    Download File
     

    STENTYS Revenues for the First 9 Months of 2013 Up 32% Over Prior Year

    24/10/2013

    STENTYS Revenues for the First 9 Months  of 2013 Up 32% Over Prior Year 


    PRINCETON, N.J. and PARIS - October 24, 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat Acute Myocardial Infarction (AMI), today announced its revenues for third-quarter 2013 and 9months through September 30, 2013.

    Download File
     

    Revenues for the First Quarter of 2013 Up 47% Over Prior Year

    25/04/2013

    STENTYS Revenues for the First Quarter of 2013 Up 47% Over Prior Year

    PRINCETON, N.J. and PARIS - 25 April 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today reports its first quarter revenues to 31 March 2013 and announces the first distributor contracts signed outside of Europe.

    Download File
     

    Revenues for the First Half of 2013 Up 43% Over Prior Year

    25/07/2013

    Revenues for the First Half of 2013 Up 43% Over Prior Year

    PRINCETON, N.J. and PARIS - 25 July 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today reports its second quarter and first half-year revenues through 30 June 2013, as well as its cash position on that date. 

    Download File
     

    2012 annual results

    28/03/2013

    STENTYS Reports 2012 Financial Results

    Further sales growth while controlling costs Solid cash position to support clinical and commercial development  Michel Darnaud appointed Chairman of the Board of Directors  

    PRINCETON, N.J. and PARIS - 28 March 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced its audited annual results for the 2012 financial year to 31 December 2012 as approved by the Board of Directors  on 27 March 2013.
     
     

    Download File
     

    Improved Bottom Line on the Company’s Historical Activity over the H1 2013

    29/08/2013

    STENTYS Reports H1 2013 Financial Results

    Improved bottom line on the Company’s historical activity  

    Dynamic growth in revenues  

    Solid cash position  


    PRINCETON, N.J. and PARIS - 29 August 2013 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announced its half-year results for the six months ending 30 June 2013, approved by the Board at its meeting on 28 August 2013.
     

    Download File
     
  • 2012

     

    STENTYS Launches New Stent-Delivery System to Facilitate Implantation in More Complex Vessel Anatomies

    26/09/2012

    STENTYS Launches New Stent-Delivery System to Facilitate Implantation in More Complex Vessel Anatomies

    PRINCETON, N.J. and PARIS – September 26, 2012 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today the European commercial release of an enhanced stent-delivery system for its SelfApposing® stent.

    Download File
     

    STENTYS Self-Apposing technology supported by breaking new scientific evidence

    26/03/2012

    STENTYS Self-Apposing technology supported by  breaking new scientific evidence

    Study points to stent sizing errors  as primary cause of heart attack récurrences


    PRINCETON, N.J., and PARIS, March 26, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the scientific rationale of its technology has been strongly supported by the conclusions of a new study by world renowned pathologist Dr. Renu Virmani (CVPath Institute, Gaithersburg, Md.), presented today at the ACC annual meeting in Chicago

    Download File
     

    STENTYS Self-Apposing® Stent continues to demonstrate low mortality at one year in APPOSITION III trial

    22/10/2012

    STENTYS Self-Apposing® Stent continues to demonstrate low mortality at one year  in APPOSITION III trial

    Interim results to be reported at TCT 2012 

    PRINCETON, N.J. and PARIS – October 22, 2012 - STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today the interim results of the APPOSITION III clinical trial for the first 600 patients at one year post treatment of a severe heart attack.

    Download File
     

    STENTYS Receives FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing® Stent

    22/10/2012

    STENTYS Receives FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing® Sten

    PRINCETON, N.J. and PARIS – October 22, 2012 – STENTYS (FR0010949404 – STNT), a medical technology company that is commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), announced today that it has received Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA) to conduct a pivotal clinical trial in the United States which, if successfully completed, will enable the Company to apply for marketing approval of the STENTYS SelfApposing stent. 

    Download File
     

    STENTYS Self-Apposing® Stent shows very low mortality at one month in 1,000 high risk heart attack patients

    16/05/2012

    STENTYS Self-Apposing® Stent shows very low mortality  at one month in 1,000 high risk heart attack patients

    APPOSITION III study results reveal mortality at 1.2%  compared to 3.5% in pooled analysis of conventional stents
     

    PRINCETON, N.J., and PARIS, May 16, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today the definite results on the 1,000 patient APPOSITION III clinical study at one month after treatment of a severe heart attack.

    Download File
     

    STENTYS to Present One-Year Interim Results From APPOSITION III Study at TCT Conference

    15/10/2012

    STENTYS to Present One-Year Interim Results From APPOSITION III Study at TCT Conference

    Satellite Symposium Also to Highlight Pr oposed U.S. Clinical Trial Program for Self-Apposing ® Stent in STEMI Patients  

    PRINCETON, N.J. and PARIS – October 15, 2012 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced today that one-year interim results from the APPOSITION III study will be presented during the Transcatheter Cardiovascular Therapeutics (TCT) conference, October 22-26, 2012 in Miami. Prof. Harald Mudra, M.D., Ph.D., of Klinikum Neuperlach (Munich, Germany) will present the results during the morning spotlight session “Primary PCI for STEMI: Drugs, Devices, and Technique Controversies” on Thursday, October 25, 2012 at 9:58 a.m.

    Download File
     

    STENTYS expands its product offerings for treating heart attacks

    14/05/2012

    STENTYS expands its product offerings for treating heart attacks

    PRINCETON, N.J., and PARIS, May 14, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today that it is launching a thrombectomy device (aspiration catheter) called STENTYS AC. 
     

    Download File
     

    STENTYS starts clinical trial to broaden portfolio with new drug-eluting stent

    14/06/2012

    STENTYS starts clinical trial to broaden portfolio with new drug-eluting stent

    APPOSITION IV clinical study to compare STENTYS new Sirolimus-DES over Medtronic DES

    PRINCETON, N.J., and PARIS, June 14, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the first patient in its APPOSITION IV clinical study using its new Self-Apposing® Sirolimus-eluting stent. The randomized study will enroll 150 heart attack patients who will be treated with either the STENTYS stent or Medtronic’s Resolute® drug-eluting stent, and will compare stent apposition in both groups at 4 and 9 months after treatment.

    Download File
     

    Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

    08/02/2012

    Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

    More patients to benefit from STENTYS technology 


    PRINCETON, N.J., and PARIS,  February 8, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the higher-price reimbursement in Germany received in 2011 for its drug-eluting stent was expanded to all coronary indications in 2012, allowing even more patients to benefit from its technology

    Download File
     

    STENTYS concludes clinical trial ahead of plan

    01/02/2012

    STENTYS concludes clinical trial ahead of plan

    Fast enrollment underscores increasing technology adoption  among 50 European hospitals in APPOSITION III study 


    PRINCETON, N.J., and PARIS, Feb. 1st, 2012 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the “APPOSITION III” clinical study successfully enrolled 1,000 patients suffering from a severe heart attack and that the final results of the examination 30 days after treatment will be presented during the upcoming EuroPCR international cardiology congress.

    Download File
     

    Revenues for the first quarter of 2012

    02/05/2012

    Revenues for the 1st quarter of 2012 up +96.5%

    STENTYS (FR0010949404 - STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, today reports its revenues for the 1st quarter to 31 March

     

    Download File
     

    2011 Financial Results

    07/03/2012

    2011 Financial Results 

    Operating expenses in loine with business plan

    Solid cash position to fuel growth

    2012 to be another pivotal year with FDA expected to approve the launch of clinical trial in the United States (IDE)

    STENTYS (FR0010949404 - STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, today reports its audited annual results for the fiscal year ending on 31 December 2011 and approved by the Board of DIrectors meeting of 6 March 2012. 

    Download File
     

    Revenues for the 3rd quarter 2011

    09/11/2012

    Revenues for the 3rd quarter 2011

    Further growth in activity 

    STENTYS (FR0010949404 - STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, todayreports its third-quarter and nine-month  year to date revenues until 30 September 2011.

    Download File
     

    Full-Year Sales for 2011

    16/01/2012

    Revenues for the 4th quarter of 2011

    Continued top line growth

    Solid cash position 

    Numerous key developments expected in 2012

    STENTYS (FR0010949404 - STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, today reports revenues for the 4th quarter and full year to 31 December 2011.

    Download File
     

    Private placement

    25/01/2012

    STENTYS launches a private placement of up to 10% of capital 


    STENTYS S.A. (“STENTYS” or the “Company”) announces today the launch of a capital increase without preferential subscription rights exclusively reserved to qualified investors through an accelerated bookbuilding for an amount of up to 10% of the share capital (the "Private Placement"). The Private Placement will be conducted in the European Economic Area and Switzerland, not including the United States of America, Canada, Australia and Japan and in accordance with Article L.411-2 II of the French Monetary and Financial Code.
     

    Download File
     

    Revenues for the first half of 2012 +92%

    25/07/2012

    Revenues for the first half of 2012 +92%

    Princenton, New Jersey and Paris, France, July 25 2012 - STENTYS (NYSE Euronext, FR0010944404 - STNT), a medical technology compant commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its unaudited revenues for the helf year ending 30 June 2012. 

    Download File
     

    STENTYS raises €8.3m in capital

    26/01/2012

    STENTYS raises €8.3m in capital

    PRINCETON, NJ and PARIS, Jan. 26, 2012 – In order to correct a typographical error, STENTYS announces that it actually issued 574,639 shares through the Private Placement. As a consequence, the aggregate amount raised was € 8.3m (instead of € 7.5m).

    Download File
     

    2012 Half-Year results

    30/08/2012

    STENTYS reports stronger operational performance during first half of 2012versus prior year

    Strong revenue growth 

    Solid cash position 

    Key events expected over the 2nd half

    Princenton, New Jersey and Paris, France, July 25 2012 - STENTYS (NYSE Euronext, FR0010944404 - STNT), a medical technology compant commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its half-year results for the 6 months to 30 June 2012, approved at the Board of DIrectors meeting on 30 August 2012

     

    Download File
     
  • 2011

     

    STENTYS reports six-month 2011 Financial results

    31/08/2011

    STENTYS reports six-month 2011 Financial results

    - Revenues soar eight-fold vs. 1H 2010

    - Cash position remains strong

    -Marketing presence in eight EU countries

    STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reported its Financial results for the six months ending 30 June 2011.

     

    Download File
     

    Revenues for the 1 half of 2011

    26/07/2011

    Revenues for the 1 half of 2011

    - Further buoyant increase in activity

    - First sales related to specific reimbursment in Germany (NUB)

    STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its revenues for the 1 half to 30 June 2011.

    Download File
     

    Increased reimbursement of STENTYS drug-eluting stent in Germany

    23/02/2011

    Increased reimbursement of STENTYS  drug-eluting stent in Germany

    PRINCETON, N.J., and PARIS, Feb. 23, 2011 — STENTYS S.A. (STNT.PA) announced today that it has received a higher price reimbursement in Germany for its drug-eluting stent

    Download File
     

    STENTYS compeltes enrollement of APPOSITION III study for its Self-Apposing Stent to Treat Heart Attacks

    21/09/2011

    STENTYS compeltes enrollement of APPOSITION III study for its Self-Apposing Stent to Treat Heart Attacks 

    PRINCETON, N.J, and PARIS, Sept. 21, 2011 - S.A. (STNT.PA), a medical technology company that is commercializing the world's first and only self-apposing stent tp treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.

     

    Download File
     

    Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board

    20/06/2011

    Prof. Gilles Montalescot  joins STENTYS Scientific Advisory Board

    PRINCETON, N.J., and PARIS, June 20, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that Gilles Montalescot, M.D., PhD, has joined its Scientific Advisory Board (SAB).

    Download File
     

    STENTYS joins Stent for Life Initiative to expand optimal heart attack treatment across Europe

    18/05/2011

    STENTYS joins Stent for Life Initiative to expand optimal heart attack treatment across Europe

    PRINCETON, N.J., and PARIS, May 18, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has joined the Stent for Life (SFL) Initiative as a key industry partner.

    Download File
     

    STENTYS expands operations into four additional European countries

    17/03/2011

    STENTYS expands operations into four additional  European countries

    PRINCETON, N.J., and PARIS, March 17, 2011 — STENTYS S.A. (STNT.PA), a medical technology company that is commercializing a new generation of innovative stents to treat acute myocardial infarction (AMI), announced today the launch of the STENTYS stents in four additional European countries: Scandinavia, Spain, Switzerland and Poland.  

     

    Download File
     

    Stenting in STEMI: Does Size Matter?

    16/05/2011

    Stenting in STEMI: Does Size Matter?

    STENTYS® Self-Apposing™ Stent for STEMI and Complex Anatomy 


    EuroPCR Symposium, Thursday, 19th May, 12:00-13:30, Room 342AB
     

    Chairmen: Prof. Patrick W. Serruys, M.D., Maurice Buchbinder, M.D.,  


    PRINCETON, N.J., and PARIS, May 16, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), is hosting a key symposium at this week’s EuroPCR congress. The symposium — “Does Size Matter?  STENTYS® Self-Apposing™ Stent for STEMI and Complex Anatomy”—will be chaired by two internationally renowned cardiologists: Prof. Patrick W. Serruys, M.D. and Maurice Buchbinder, M.D. Registered participants of the EuroPCR congress are eligible to attend.

    Download File
     

    Over 1000 patients have benefited from STENTYS Self-Apposing technology

    15/09/2011

    Over 1000 patients have benefited from STENTYS Self-Apposing technology 

    PRINCETON, N.J., and PARIS, Sept.15, 2011 - STENTYS S.A (FR0010949404, STNTP.PA), a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that its Self-Apposing Stent has been implanted into more than 1000 patients internationally. 

     

    Download File
     

    STENTYS Self-Apposing Stents in “perfect apposition to vessels” after treating patients with heart attacks

    12/10/2011

    STENTYS Self-Apposing Stents in “perfect apposition to vessels”  after treating patients with heart attacks

    “APPOSITION I” study published in leading medical journal EuroIntervention 


    PRINCETON, N.J., and PARIS, Oct. 12, 2011 — STENTYS S.A. (STNT.PA), a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today the publication of the results of the “APPOSITION I” clinical study results in the September issue of the medical journal EuroIntervention,

    Download File
     

    Outstanding interim results of STENTYS international clinical study of 600 heart attack patients

    08/11/2011

    Outstanding interim results of STENTYS international clinical study of 600 heart attack patients

    Lower rate of adverse events for STENTYS Self-Apposing™ Stent compared to reported results of conventional stents   


    PRINCETON, N.J., and PARIS, Nov. 8, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), disclosed today data on 600 patients from its ongoing “APPOSITION III” international clinical study who underwent an examination 30 day after treatment of a severe heart attack. 
     

    Download File
     

    STENTYS recruits Country Managers for France and Italy

    08/06/2011

    STENTYS recruits Country Managers for France and Italy 

    STENTYS (FR0010949404 - STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it is starting the marketing of the STENTYS stents in France and Italy.

     

    Download File
     

    STENTYS enrolls first 250 patients, half of Apposition III study of its Self-Apposing Stent for treatment of Heart Attacks

    02/05/2011

    STENTYS enrolls first 250 patients, half of Apposition III study of its Self-Apposing Stent for treatment of Heart Attacks

    PRINCETON, N.J., and PARIS, May 2, 2011 — STENTYS S.A. (STNT.PA), a medical technology company that is commercializing a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announced today that it has reached the mid-point of its international APPOSITION III study of its Self-Apposing Stent, with 250 patients now enrolled out of a total of 500. The trial primary endpoint is Major Adverse Cardiac Events (MACE) at 12 months post-procedure.

    Download File
     

    Full year 2010 revenues

    08/02/2011

    Substantial revenue increase in Q4 2010

    Sales grew by +66.7% in the 4th quarter of 2010 vs. the 3nd quarter of 2010

    STENTYS (FR0010949404 - STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, today reports its 2010 annual revenues for the period ending on December 31 2010. 

    Download File
     

    Significant revenue increase in the 1st quarter of 2011

    11/05/2011

    STENTYS Significant revenue increase in the 1st quarter of 2011

    STENTYS (FR0010949404 - STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, today reported its revenues for the 1 quarter to 31 March 2011

    Download File
     

    Financial agenda for 2012

    13/12/2011

    Financial events : agenda 2012

    Download File
     

    Financial events for 2011

    24/01/2011

    Financial events : agenda 2011

    Download File
     

    2011 FY 2010 financial results

    24/03/2011

    STENTYS reports FY 2010 Financial results

    Operational expenses aligned with plan

    Solid cash position to continue myocardial infarction market development

    STENTYS (FR0010949404 - STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, reported today its audited annual Financial statements for the fiscal year 2010, ending December 31, 2010, and approved by the company Board of Directors on March 23 2011.

     

    Download File
     
  • 2010

     

    Launch of APPOSITION III - 50 patients already enrolled

    09/12/2010

    STENTYS begins large-scale, “real life” study with its selfapposing stent for treatment of Heart Attacks  


    50 patients already enrolled 


    PRINCETON, N.J., and PARIS, Dec. 09, 2010 — STENTYS S.A. (STNT.PA), which develops innovative stents to treat Acute Myocardial Infarction (AMI), announced today that it has begun the international APPOSITION III study of its self-apposing stent, with 50 patients already enrolled out of a total of 500. The trial primary endpoint is Major Adverse Cardiac Events at 12 months post-procedure.

    Download File
     

    First step towards Initial Public Offering on the Paris NYSE Euronext market

    09/09/2010

    First step towards Initial Public Offering on the Paris NYSE Euronext market 


    STENTYS files its « Document de Base » with the French Autorité des marchés financiers 


    STENTYS, a medical technology company which has dev eloped a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announces the filing of its “Document de Base” by the Autorit é des marchés financiers (AMF), the French market reg ulator, under registration n° I.-10- 067 dated 09th September 2010. This is the first step towards the Initial Public Offering of its shares on the Paris NYSE Euronext market. 

    Download File
     

    STENTYS launches its initial public offering on NYS E Euronext Paris

    12/10/2010

    STENTYS launches today its initial public offering and proposed listing of its shares on NYSE Euronext Paris, C Compartment. 

    The French securities regulator (l’Autorité des marchés financiers – the AMF) granted visa n° 10-362 on October 12th 2010 to the prospectus relating to STENTYS’ initial public offering (comprising its Document de Base registered on September 9th, 2010 under number I.10-067, and a note d’opération, which includes a summary).

    Download File
     

    Steady Growth in Q3 2010

    15/11/2010

    Steady Growth in Q3 2010

    Increasing interest of STENTYS' innovative stents among European cardiologists following positive results of the APPOSITION II study 

    STENTYS (FR0010949404 – STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, today reports its third-quarter revenues and nine-month year-to-date revenues. 
     

    Download File
     

    Definitive amount of capital increase and Communication regarding the details of stabilisation operations

    19/11/2010

    Definitive amount of capital increase and Communication regarding the details of stabilisation operations

    The Lead Manager and Bookrunner of the issue by STENTYS (the Company) of new shares on the occasion of its admission for trading on the regulated market of NYSE Euronext Paris has informed the company that it has not exercised the over-allotment option granted to it. As a result the definitive amount of the capital increase is approximately €22.7 million, corresponding to the issue of 1,893,939 new shares.

    Download File
     

    Successful IPO of STENTYS on NYSE Euronext Paris

    22/10/2010

    The Public Offering was more than twice oversubscribed and the Global Placement 1.1 time

     
    Offering Price: €12.00  per share
     
    Amount of the offer:  €22.7 million, before the exercise of the over-allotment option
     
    Trading to begin on October 25th, 2010 in the form of promises of shares 


    STENTYS, a medical technology company that markets a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), has announced the final terms of its initial public offering (IPO) on Euronext Paris (Compartment C, ISIN: FR0010949404 – Ticker: STNT).
     

    Download File
     

    STENTYS appoints Michel Darnaud to its Board of Directors

    23/11/2010

    STENTYS appoints Michel Darnaud  to its Board of Directors

    PRINCETON, N.J., and PARIS, Nov. 23, 2010—STENTYS (STNT.PA), a medical technology company that markets a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announced today that its board of directors has nominated Michel Darnaud as a director.  

    Download File
     

Page ID 1241   |   Last edited 2017/10/16